Decision to Stop Dosing in Tominersen Trial ‘Pretty Hard to Take’

Decision to Stop Dosing in Tominersen Trial ‘Pretty Hard to Take’

293832

Decision to Stop Dosing in Tominersen Trial ‘Pretty Hard to Take’

Sarah Lynn Mays learned she wouldn’t be returning to Northwestern University for her scheduled intrathecal injection of tominersen when her younger sister called to give the news — Roche was stopping dosing for its Phase 3 clinical trial of the Huntington’s disease treatment. Sarah Lynn Mays with her husband Daniel Mays. (Courtesy of Sarah Lynn Mays) It felt “almost like losing someone twice,” said Mays, 40, in a phone interview with Huntington’s Disease News from her Chicago home.…

You must be logged in to read/download the full post.